Delay, I'm looking at it favourably after listening to the call and Q&A's and regarding it more of a mitigating risk issue. They would only have F3 data from 6-8 boys ready for this Summer if they took that approach and that data may not show significance and, therefore, knock confidence in the programme. It is better to wait for the full 20 boys on the 24 week biopsy route and that would include F6 cases too.
PRV, as I understand it if the programme is still running would be awarded… Read More
Sarepta (market cap $1,580m) is in trouble over claims for its DMD candidate Eteplirsen - Scott + Scott lawyers trying to start a shareholder class action http://tinyurl.com/mykqdtx . Perhaps holders will switch to Summit (market cap $160m)
Hi everyone ! Here’s hoping that the DMD delay is purely clinical administration issues in getting DMD boys ready for treatment , rather than lack of F3 evidence treatment benefit .
Seems to be extra info due to be reported though !
Note SUMM are now saying 20 patients “We now look forward to providing the full analysis of 24-week biopsies from the approximately 20 patients dosed with the F3 or F6 formulation of ezutromid, plus 24-week MRI and functional… Read More
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.